Biohaven. Every tracked FinTwit mention of $BHVN, newest first. 8 mentions since the first on Sep 25, 2025. See the price chart.
November 2025 · 6 mentions
Nov 6
Adam Feuerstein ✡️ — On $BHVN --
The agency was more than likely correct to reject Biohaven's treatment for SCA. At the very least, the decision announced Tuesday night was not a surprise to anyone…↗
Nov 6
Adam Feuerstein ✡️ — This week's Biotech Scorecard newsletter: The FDA is a mess, but don't blame it for everything
I write about $QURE and $BHVN
Re: Uniqure and its gene therapy for Huntington's di…↗
Nov 5
Adam Feuerstein ✡️ — $BHVN approval was a coin flip at best, so the CRL and the reasons for it are not really a surprise. $QURE is different in some ways.
This is what I wrote on Oct. 9
We should le…↗
Adam Feuerstein ✡️ — $QURE $BHVN The question I (we) now struggle to understand:
Is the "new" FDA now uniformly opposed to using external /historical controls in drug applications?
Or
Were there si…↗
Adam Feuerstein ✡️ — The limits of FDA flexibility are tested as a controversial Biohaven $BHVN drug decision nears https://t.co/MaqnNoshrV↗
September 2025 · 1 mention
Sep 25
Adam Feuerstein ✡️ — @avidresearch I don't know anything about the $BHVN external control or how it was constructed, so I can't comment. $QURE is sourcing its ECA from a very large, independent and wel…↗